

# **LIVER CANCER: Advances in Science and Clinical Management**

**FRIDAY, DECEMBER 11, 2020**

**LIVE VIRTUAL ACTIVITY**



**Program Director**

**Josep M. Llovet, MD, PhD**

*Co-Director, Mount Sinai Liver Cancer Program*

**Sponsored by**

**Mount Sinai Liver Cancer Program**

**Tisch Cancer Institute**



**Mount  
Sinai**


*The Tisch Cancer Institute*

**LIVER CANCER:**  
*Advances in Science and Clinical Management*

**FRIDAY, DECEMBER 11, 2020**

**PROGRAM**

- 8:30 – 9:00am**      **Registration**
- 9:00 – 9:10am**      **Welcome and Opening**  
Ramon Parsons, MD, PhD, Director, Tisch Cancer Institute
- 9:10 – 9:40am**      **Achievements of Mount Sinai Liver Cancer Program 2005-20**  
Josep M. Llovet, MD, PhD, Co-Director Mount Sinai Liver Cancer Program, Division of Liver Diseases
- 9:40 – 10:20am**      **Hans Popper Lecture**  
*Introduction:* Josep M. Llovet, MD, PhD, Co-Director Mount Sinai Liver Cancer Program, Division of Liver Diseases  
**Precision Medicine in Cholangiocarcinoma**  
Gregory Gores, MD, PhD, Mayo Clinic, Rochester, Minnesota
- 10:20 – 10:40am**      **Coffee Break**
- 
- 10:40 – 12:00pm**      **PATHOGENESIS OF LIVER CANCER**  
*Chairman:* Scott Friedman, MD, Dean of Therapeutic Discovery, Co-Director Mount Sinai Liver Cancer Program
- 10:40 – 11:10am**      **Overview: From Fibrosis to Liver Cancer**  
Scott Friedman, MD, Dean of Therapeutic Discovery, Co-Director Mount Sinai Liver Cancer Program
- 11:10 – 11:30am**      **Linking Pathology with Molecular Types of HCC and iCCA**  
Swan Thung, MD, Pathology, Molecular & Cell Based Medicine, Mount Sinai Liver Cancer Program
- 11:30 – 12:00pm**      **Rationale for Early Immunotherapy Treatment in HCC**  
Miriam Merad, MD, PhD, Director Precision Immunology Institute, Department of Oncological Sciences, Department of Hematology and Medical Oncology
- 12:00 – 12:40pm**      **Lunch**
- 
- 12:40 – 1:40pm**      **MANAGEMENT OF LIVER CANCER (EARLY-INTERMEDIATE STAGE)**  
*Chairman:* Myron Schwartz, MD, Mount Sinai Liver Cancer Program, Director of Liver Surgery, Recanati/Miller Transplantation Institute
- 12:40 – 1:00pm**      **Advances in the Resection and Transplantation for HCC and iCCA**  
Myron Schwartz, MD, Mount Sinai Liver Cancer Program, Director of Liver Surgery, Recanati/Miller Transplantation Institute
- 1:00 – 1:20pm**      **Chemoembolization (TACE) and Radioembolization (TARE) in HCC**  
Edward Kim, MD, Department of Radiology, Department of Surgery, Mount Sinai Liver Cancer Program



- 1:20 – 1:40pm **SBRT for Early and Intermediate HCC. Where Do We Stand?**  
Michael Buckstein, MD, PhD, Department of Radiation Oncology
- 1:40 – 2:00pm **Coffee Break**
- 
- 2:00 – 3:20pm **MANAGEMENT OF LIVER CANCER (ADVANCED STAGE)**  
*Chairman:* Josep M. Llovet, MD, PhD, Co-Director Mount Sinai Liver Cancer Program, Division of Liver Diseases
- 2:00 – 2:30pm **Molecular and Immune Therapies in Advanced HCC**  
Josep M Llovet, MD, PhD, Co-Director Mount Sinai Liver Cancer Program, Division of Liver Diseases
- 2:30 – 2:50pm **New Emerging Therapies in Cancer and HCC- Phase I Studies**  
Thomas Marron, MD, PhD, Department of Medicine, Hematology and Medical Oncology, Tisch Cancer Institute
- 2:50 – 3:20pm **State-of-the-Art Lecture**  
**Implications of COVID-19 in the management of HCC: ILCA Guidelines**  
Augusto Villanueva, MD, PhD, Mount Sinai Liver Cancer Program, Division of Liver Diseases
- 3:20 – 3:40pm **Coffee Break**
- 
- 3:40 – 4:40pm **NOVEL TARGETS AND PRE-CLINICAL MODELS FOR LIVER CANCER TREATMENT**  
*Chairman:* Samuel Waxman, MD, Mount Sinai Liver Cancer Program, Department of Hematology and Medical Oncology, Department of Oncological Sciences
- 3:40 – 4:00pm **New Perspective on the Molecular and Immune Classification of Intra and Extrahepatic cholangiocarcinoma**  
Daniela Sia, PhD, Mount Sinai Liver Cancer Program, Division of Liver Diseases
- 4:00 – 4:20pm **Wnt Signaling and Immune Response, What We Know from Experimental Models**  
Amaia Lujambio, PhD, Department of Oncological Sciences
- 4:20 – 4:40pm **Organoids and Other Patient-derived Preclinical Models of Liver Cancer**  
Ernesto Guccione, PhD, Department of Oncological Sciences
- 4:40pm **Closing Remarks**

## Conference Information

<https://mssm.cloud-cme.com>

Office of CME at 212-731-7950 • e-mail: [cme@mssm.edu](mailto:cme@mssm.edu)



**Icahn School  
of Medicine at  
Mount  
Sinai**

**PROGRAM DIRECTOR**

**JOSEP M. LLOVET, MD, PhD**

Co-Director Mount Sinai Liver Cancer Program, Division of Liver Diseases

**PROGRAM CHAIRS**

**SCOTT FRIEDMAN, MD**

Dean of Therapeutic Discovery, Co-Director Mount Sinai Liver Cancer Program,  
Division of Liver Diseases

**MYRON E. SCHWARTZ, MD**

Mount Sinai Liver Cancer Program, Director of Liver Surgery,  
Recanati/Miller Transplantation Institute

**SAMUEL WAXMAN, MD**

Professor of Medicine, Department of Hematology and Medical Oncology,  
Department of Oncological Sciences

**GUEST FACULTY**

**GREGORY GORES, MD, PhD**

Executive Dean for Research, Mayo Clinic

**HOST FACULTY**

**MICHAEL BUCKSTEIN, MD, PhD**

Department of Radiation Oncology

**SCOTT FRIEDMAN, MD**

Dean of Therapeutic Discovery, Co-Director Mount Sinai Liver Cancer Program

**ERNESTO GUCCIONE, PhD**

Department of Oncological Sciences

**EDWARD KIM, MD**

Department of Radiology, Department of Surgery,  
Mount Sinai Liver Cancer Program

**JOSEP LLOVET, MD, PhD**

Co-Director Mount Sinai Liver Cancer Program, Division of Liver Diseases

**AMAIA LUJAMBIO, PhD**

Department of Oncological Sciences

**THOMAS MARRON, MD, PhD**

Department of Medicine, Hematology and Medical Oncology, Tisch Cancer Institute

**MIRIAM MERAD, MD, PhD**

Director Precision Immunology Institute, Department of Oncological Sciences,  
Department of Hematology and Medical Oncology

**RAMON PARSONS, MD, PhD**

Director, Tisch Cancer Institute

**MYRON SCHWARTZ, MD**

Mount Sinai Liver Cancer Program, Director of Liver Surgery,  
Recanati/Miller Transplantation Institute

**DANIELA SIA, PhD**

Mount Sinai Liver Cancer Program, Division of Liver Diseases

**SWAN THUNG, MD**

Pathology, Molecular & Cell Based Medicine, Mount Sinai Liver Cancer Program

**AUGUSTO VILLANUEVA, MD, PhD**

Mount Sinai Liver Cancer Program, Division of Liver Diseases

**SAMUEL WAXMAN, MD**

Mount Sinai Liver Cancer Program, Department of Hematology and Medical Oncology,  
Department of Oncological Sciences

## Activity Learning Objectives

- Understand the epidemiology and disparities of liver cancer in the US.
- Review the current role of surgical and loco-regional treatments for liver cancer.
- Critical review of molecular therapies and SBRT in the management of advanced HCC
- Understand the molecular rationale for immune therapies in HCC.

## Activity Description

This virtual activity will assemble multidisciplinary experts on chronic liver diseases, hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA) from the Mount Sinai Liver Cancer Program and one outstanding invited lecturer. The meeting is intended to provide a summary of the state-of-the-art knowledge of the novel advancements reported in 2020 on the pathogenesis and clinical management of liver cancer, including the research conducted in Mount Sinai.

## Target Audience

Hepatologists and Gastroenterologist, Oncologists, Surgeons, Radiologist, Pathologists and Basic Scientists interested in liver cancer from the New York Area and beyond.

## Accreditation

The Icahn School of Medicine at Mount Sinai is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

## Credit Designation

The Icahn School of Medicine at Mount Sinai designates this live internet activity for a maximum of **7.0 AMA PRA Category 1 Credit(s)**<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

## Verification of Attendance

Verification of attendance will be provided to all professionals.

## Special Needs

The Icahn School of Medicine at Mount Sinai is in full compliance with provisions of the Americans with Disabilities Act (ADA) and is accessible for individuals with special needs. If you would like to attend this conference and require any special needs or accommodations please contact the Page and William Black Post-Graduate School of Medicine at 212-731-7950.

## Faculty Disclosure

It is the policy of the Icahn School of Medicine at Mount Sinai to ensure objectivity, balance, independence, transparency, and scientific rigor in all CME-provided educational activities. All faculty participating in the planning or implementation of a provided activity are expected to disclose to the audience any relevant financial relationships and to assist in resolving any conflict of interest that may arise from the relationship. Presenters must also make a meaningful disclosure to the audience of their discussions of unlabeled or unapproved drugs or devices. This information will be available as part of the course materials.

## Registration

<https://mssm.cloud-cme.com>

## Registration Fee

Registration is complimentary

## Acknowledgement

This activity is made possible in part by educational grants from:

**BMS, Celsion, Eisai, Inc., Merck Sharpe & Dohme, Corp.**

**Icahn School of Medicine at Mount Sinai**  
The Page and William Black Post Graduate School  
One Gustave L. Levy Place, Box 1193  
New York, NY 10029-6574

**MOUNT SINAI LIVER  
CANCER PROGRAM 15<sup>TH</sup> ANNIVERSARY**

***LIVER CANCER:  
Advances in Science and  
Clinical Management***



Tisch Cancer Institute  
Icahn School of Medicine at Mount Sinai

**Complimentary Online Registration**